ascopubs.org

TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not include a full text ...
ascopubs.org

Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with ...

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19). This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting ...